TABLE 2: Cost effectiveness and Incremental Cost-Effectiveness Ratio.
| Diagnostic Test | Mean Cost | Effectiveness | Cost | Incremental | Incremental | ICER |
|---|---|---|---|---|---|---|
| (US$) | (negative culture | Effectiveness | Effectiveness | Cost | (US$) | |
| and clinical improvement) | (US$) | (US$) | ||||
| DST-MGIT | 67.13 | 80.55 | 0.83 | - | - | - |
| Xpert with subsidy | 33.48 | 94.12 | 0.36 | 13.57 | dominated | dominated |
| Xpert without subsidy | 175.24 | 94.12 | 1.86 | 13.57 | 108.11 | 7.97 |
Legend: American dollar conversion value US$1.00 = R$ 2,0165 on September 11, 2012. ICER: incremental cost-effectiveness ratio; DST: drug susceptibility test; MGIT: BactecTMMGITTM960 System; Xpert: Xpert®MTB/RIF; ICER: Incremental Cost-Effectiveness Ratio.